Thanks Jia!

This first study has sparked several ongoing phase-2 studies nationwide (glioblastoma, bladder and prostate cancer). Early data from these studies look promising, we look forward to reporting this! Incredibly grateful to the patients, families, philanthropic/federal support to make this possible

Preclinical work by Polina Weitzenfeld confirmed that 2142-V11 induces TLS formation across tumor models & drives antitumor responses even without lymph node trafficking, opening tons of mechanistic questions about TLS function, IT delivery and exciting avenues for subsequent combination approaches!

Another unexpected discovery was that IT 2141-V11 not only was safe but appear to trigger tertiary lymphoid structures (TLS) formation. These findings not only supports intratumoral administration as a safe approach but also the most effective way to promote optimal immune activation/interactions

Led by David Knorr, our phase trial (12 pts) showed that IT 2141-V11 was safe, and in two patients, led to sustained CR in both injected and distant, non-injected lesions, validating over a decade of preclinical findings using our humanized mouse models!

CD40 agonists have shown promise but failed due to toxicity and weak activity. We previously showed that 2141-V11, Fc-engineered for increased FcγRIIB binding, leads to superior antitumor activity and reduced toxicity when given intratumorally in preclinical models, paving the way for this trial.

Same here… submitted in February 2024. Council met in September. Still waiting…

Same here, under my RFA only 3 awarded for FY25, all done from 1/16 to 1/30. Nothing after Feb 1st…

Great point, just looked! Will see if numbers of new awards start coming up in the following days 🙏🏻

I am exactly on the same boat, still waiting, despite these transient pauses and hearing that some people are getting NOAs I also have not heard a word…frustrating is a kind way to describe the feeling…